480449-70-5 | Edoxaban

Packsize	Purity	Availability	Price	Discounted Price
5mg	95%	in stock	$11.00	$8.00
10mg	95%	in stock	$13.00	$9.00
50mg	95%	in stock	$16.00	$11.00
100mg	95%	in stock	$19.00	$13.00
250mg	95%	in stock	$28.00	$20.00
1g	95%	in stock	$59.00	$42.00
5g	95%	in stock	$217.00	$152.00
25g	95%	in stock	$1,067.00	$747.00

Description

• Catalog Number: AG19513
• Chemical Name: Edoxaban
• CAS Number: 480449-70-5
• Molecular Formula: C24H30ClN7O4S
• Molecular Weight: 548.0575
• MDL Number: MFCD29477765
• SMILES: CN1CCc2c(C1)sc(n2)C(=O)N[C@@H]1C[C@H](CC[C@@H]1NC(=O)C(=O)Nc1ccc(cn1)Cl)C(=O)N(C)C

Computed Properties

• Complexity: 880
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 3
• Heavy Atom Count: 37
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 5
• XLogP3: 1.4

Literature

• Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.

  Clinical pharmacokinetics 20160101

• Overview of the new oral anticoagulants: opportunities and challenges.

  Arteriosclerosis, thrombosis, and vascular biology 20150501

• Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.

  Seminars in thrombosis and hemostasis 20150301

• The role of factor Xa inhibitors in venous thromboembolism treatment.

  Vascular health and risk management 20150101

• Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.

  Thrombosis and haemostasis 20121101

• Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.

  Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20121001

• Oral direct factor Xa inhibitors.

  Circulation research 20120928

• Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.

  Thrombosis research 20120901

• The promise of novel direct oral anticoagulants.

  Best practice & research. Clinical haematology 20120901

• Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.

  Thrombosis and haemostasis 20120701

• Long-term benefits of preventing venous thromboembolic events.

  Current medical research and opinion 20120601

• Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.

  Critical pathways in cardiology 20120601

• In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.

  Thrombosis research 20120401

• Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation.

  Circulation journal : official journal of the Japanese Circulation Society 20120101

• Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.

  Thrombosis and haemostasis 20111201

• Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.

  Thrombosis and haemostasis 20111201

• [Current status and future of anti-Xa inhibitors].

  Rinsho shinkeigaku = Clinical neurology 20111101

• The new oral anticoagulants.

  Clinical medicine (London, England) 20111001

• Edoxaban for the prevention of thromboembolic events after surgery.

  Drugs of today (Barcelona, Spain : 1998) 20111001

• [Thromboembolic prophylaxis 2011: is warfarin on the wane?].

  Giornale italiano di cardiologia (2006) 20110901

• Edoxaban: a new oral direct factor xa inhibitor.

  Drugs 20110820

• Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.

  Future cardiology 20110701

• [New anticoagulants in the prevention and treatment of venous thromboembolism].

  Orvosi hetilap 20110619

• Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.

  Thrombosis and haemostasis 20110601

• Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.

  Thrombosis and haemostasis 20110301

• Factor Xa and thrombin as targets for new oral anticoagulants.

  Thrombosis research 20110101

• Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.

  Annual review of medicine 20110101

• Edoxaban tosylate.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20110101

• A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.

  Journal of thrombosis and haemostasis : JTH 20101101

• Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.

  Thrombosis research 20101001

• Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).

  American heart journal 20101001

• Factor Xa inhibitors: next-generation antithrombotic agents.

  Journal of medicinal chemistry 20100909

• Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.

  Thrombosis and haemostasis 20100901

• Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.

  Thrombosis and haemostasis 20100901

• [Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100801

• Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.

  Journal of clinical pharmacology 20100701

• Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.

  Current opinion in cardiology 20100701

• New anticoagulants for atrial fibrillation.

  Seminars in thrombosis and hemostasis 20090701

• DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.

  Journal of thrombosis and haemostasis : JTH 20080901

• New oral anticoagulants in atrial fibrillation.

  European heart journal 20080101